WAKEFIELD, Mass., April 05, 2017 -- Edgewater Technology, Inc. (NASDAQ:EDGW) (Edgewater), a leading consulting firm that brings a blend of classic and product-based consulting services to its clients, will hold a conference call for analysts on Wednesday, May 3, 2017 at 10:00 a.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2017. The company will issue its financial results in a press release prior to the call.
Date: Wednesday, May 3, 2017
Time: 10:00 a.m. Eastern Time
Dial-in number: 1-877-713-9347 / Passcode: 3108971
Webcast: http://ir.edgewater.com/
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.
Edgewater’s news release containing the first quarter 2017 financial results will be released prior to the market opening on the day of the call. A replay of the conference call can be accessed via Edgewater’s investor relations web site at http://ir.edgewater.com/ or by dialing 1-404-537-3406 (Conference ID#: 3108971) after 1:00 p.m. Eastern time on the same day through Wednesday, May 17, 2017.
About Edgewater
Edgewater Technology, Inc. (NASDAQ:EDGW) is a strategic consulting firm delivering a blend of classic and product-based consulting services. Edgewater addresses the market both vertically by industry and horizontally by product and technology specialty, providing its client base with a wide range of business and technology solutions. As one of the largest IT consulting firms based in New England, the company works with clients to reduce costs, improve processes and increase revenue through the judicious use of technology. Edgewater’s brand names include Edgewater Technology, Edgewater Ranzal and Edgewater Fullscope. To learn more, please visit www.edgewater.com.
Safe Harbor for Forward-Looking Statements
During the course of the conference call, Edgewater may make forward-looking statements regarding future events or the future financial performance of the Company. Statements including words such as "anticipate," "believe,” "estimate" or "expect" and statements in the future tense are forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual events or actual future results to differ materially from those set forth in the forward-looking statements. Please refer to Edgewater’s latest Annual Report on Form 10-K for the fiscal year ended December 31, 2016 for a discussion of important factors that could cause actual events or actual results to differ materially from those discussed during the conference call.
Company Contact: Timothy R. Oakes, Chief Financial Officer 1-781-246-3343


NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal
AFT Leaves X Over AI-Generated Images of Minors
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 



